表观遗传学
精密医学
DNA甲基化
个性化医疗
癌症
小RNA
乳腺癌
医学
生物信息学
计算生物学
生物
内科学
遗传学
病理
基因表达
基因
作者
Jesús Beltrán-García,Rebeca Osca-Verdegal,Salvador Mena-Mollá,José Luis García-Giménez
标识
DOI:10.3389/fgene.2019.00621
摘要
Epigenetic alterations play a key role in the initiation and progression of cancer. Therefore, it is possible to use epigenetic marks as biomarkers for predictive and precision medicine in cancer. Precision medicine is poised to impact clinical practice, patients and healthcare systems. The objective of this review is to provide an overview of the epigenetic testing landscape in cancer by examining commercially available epigenetic-based in vitro diagnostic tests for colon, breast, cervical, glioblastoma, lung cancers, and for cancers of unknown origin. We compile current commercial epigenetic tests based on epigenetic biomarkers (i.e. DNA methylation, miRNAs, and histones) that can actually be implemented into clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI